Founded 2013, Aerobiotix has developed a novel suite of FDA 510(k) cleared hospital-based air decontamination products and its devices are supported by multiple peer-reviewed research studies. Aerobiotix devices, such as the operating-room based ILLUVIA system, are used by leading healthcare centers to reduce bacterial and viral contamination, including SARS-CoV-2 and other emerging pathogens.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/07/21 | $25,000,000 | Growth |
Asahi Kasai Ventures Vivo Capital  | undisclosed |
